Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer · Akebia Therapeutics, Inc. (AKBA)

Erik Ostrowski

A named executive officer of Akebia Therapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,792,361

FY2024: $1,215,122

Compensation figures as of the proxy filed April 28, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-09-24.

Erik Ostrowski compensation by year

Akebia Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Akebia Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$284,414$552,919
Bonus$0$0
Stock awards$357,000$436,576
Option awards$445,310$562,915
Non-equity incentive$127,825$223,074
Pension and deferred compensation$0$0
All other$573$16,877
Total$1,215,122$1,792,361

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Akebia Therapeutics, Inc. DEF 14A filed April 28, 2026, accession 0001517022-26-000034, and prior-year filings. Open the filing on EDGAR.

$1.2M
$1.8M
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU428,234$689,457—
Option292,300—$2.24
Option312,500—$1.02

Per the Outstanding Equity Awards at Fiscal Year-End table in Akebia Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2025 proxy (filed April 28, 2026)
current to 2026-09-24 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-29Sale10b5-156,019$1.11616,616

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Akebia Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
John ButlerPresident and Chief Executive Officer$5,652,339
Steven BurkeSenior Vice President, Chief Research & Development and Medical Officer$1,859,815
Erik Ostrowski · this pageSenior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer$1,792,361
Nicholas GrundSenior Vice President, Chief Commercial Officer$1,728,405

The full Akebia Therapeutics compensation record

free company brief

This page is one person within Akebia Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Akebia Therapeutics's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Akebia Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Velarion Pro: every company page, peer tools and exports, one seat

One email to you when Pro opens, and nothing else. Privacy